PCAC July 2026 meeting: what the advisory committee is reviewing

The FDA's Pharmacy Compounding Advisory Committee met in July 2026. Here is what it does, what was on the agenda, and why the outcome matters.

Update, September 14, 2026: The committee met on July 23–24, 2026. It voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list. It voted against recommending emideltide (DSIP). The votes are advisory, and FDA has not made a final decision. The rest of this article is a preview written before the meeting.

TL;DR

• PCAC is the FDA advisory body that reviews which substances compounding pharmacies are allowed to use.
• On July 23–24, 2026, the committee reviewed seven peptides that FDA removed from Category 2 on April 22, 2026. It voted to recommend six of them and voted against emideltide (DSIP).
• A PCAC recommendation is not a final rule. As of September 14, 2026, FDA has not made a final decision.

What the PCAC is

The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory panel. It reviews scientific and policy questions about which drugs and substances compounding pharmacies may legally prepare. Think of it as a jury that weighs the evidence — FDA then decides what to do with the verdict.

The committee evaluates substances placed on the bulk drug substances lists under the Drug Quality and Security Act (DQSA) of 2013 (FDA, Drug Quality and Security Act framework, 2013). For peptides, this process has shaped access to compounds like BPC-157, TB-500, and others since 2023.

How the review process works

PCAC meetings follow a structured format. Researchers, physicians, and pharmacy stakeholders present data. Committee members deliberate and vote on whether a substance presents sufficient clinical need and safety evidence to remain available through compounding.

A positive recommendation does not restore access immediately. It signals to FDA that the evidence supports reclassification. The formal step — a Federal Register notice — must still follow. That process can take months.

Who watches the PCAC closely

People come to this topic when they are waiting on a peptide that is currently restricted. Physicians, compounding pharmacists, and patients tracking whether a Category 2 substance might regain Category 1 status monitor each PCAC meeting for signals.

The July 2026 session mattered because it reviewed seven peptides that FDA removed from Category 2 on April 22, 2026, after their nominations were withdrawn. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.

What the research base looks like

The PCAC weighs published literature — including peer-reviewed clinical studies, preclinical data, and post-market surveillance — against evidence of clinical need. For peptides under review, the research base is largely preclinical or small-scale human studies, which is why the committee process exists: to set a threshold for how much evidence is enough.

What to know before drawing conclusions

PCAC recommendations are non-binding. FDA is not obligated to act on them, and timelines slip. As of September 14, 2026, FDA has not made a final decision on the July 2026 votes. Physicians and patients should not assume access is restored until that step completes.

The Halftime POV

At Halftime Health, we follow each PCAC cycle closely — not because we expect overnight changes, but because the regulatory trajectory shapes what responsible clinical access looks like over time. We only prescribe through licensed physicians in states where our partner physicians are credentialed, and we update our formulary when rules change, not in anticipation of them.

Related reading:

• PCAC advisory committee explained
• FDA reclassification April 2026 explained
• Why some peptides are still Category 2
• BPC-157 availability in 2026
• Peptide regulatory landscape 2026

---

FAQ

Q: What is the PCAC advisory committee? A: PCAC stands for the Pharmacy Compounding Advisory Committee. It is an FDA advisory body that reviews scientific and policy questions about drug compounding, including which substances belong on the Section 503A bulk drug substances list. FDA also keeps interim category lists: Category 1 is for substances under evaluation, and Category 2 is for substances that raise significant safety risks.

Q: What does PCAC review in 2026? A: At its July 23–24, 2026 meeting, PCAC reviewed seven peptides for the Section 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon. FDA had removed all seven from Category 2 on April 22, 2026, after their nominations were withdrawn. The committee voted to recommend six of them and voted against recommending emideltide (DSIP). The committee is advisory, and FDA makes the final decision.

Q: Will peptides be reclassified in 2026? A: FDA already changed its category list in 2026. It removed 12 peptides from Category 2 on April 22, 2026, after their nominations were withdrawn. The July 2026 PCAC meeting produced recommendations, not a final rule. As of September 14, 2026, FDA has not published a final decision, proposed rule, or updated category list acting on those votes. Timelines can shift, and no outcome is guaranteed.

---

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA — Pharmacy Compounding Advisory Committee (2024)
• FDA — Drug Quality and Security Act, Compounding (2013)

---